30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
Finland Biotechnology & Medical Research

Faron Pharmaceuticals Oy (FARN)

Track

The most recent insider trading activity occurred on March 1, 2026, with significant buy transactions totaling over $700,000 by executives Sirpa Jalkanen and Tuomo Pätsi. Prior to this, on April 3, 2024, multiple directors, including Markku Jalkanen, Tuomo Pätsi, and Sirpa Jalkanen, also made substantial buy transactions. Earlier sell transactions were noted in October 2023.
Stock chart
Ticker: FARN Exchange: LSE
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Tuomo Pätsi
Non-Executive Chairman
1 purchase — total 200,001 EUR
Buy 1 Mar 2026
Value €1,156,482.83 | Price 13.79 | Shares 59,740
Buy 1 Mar 2026
Value €1,791,182.05 | Price 265.53 | Shares 87,167
Buy 3 Apr 2024
Value €119,998.50 | Price 1.50 | Shares 79,999
Buy 3 Apr 2024
Value €119,998.50 | Price 1.50 | Shares 79,999
Buy 3 Apr 2024
Value €119,998.50 | Price 1.50 | Shares 79,999
Sale 12 Oct 2023
Value €19,129.50 | Price 3.83 | Shares 5,000
Sale 3 Oct 2023
Value €18,604.50 | Price 3.72 | Shares 5,000
Buy 5 Apr 2022
Value €70,532.50 | Price 2.82 | Shares 25,000
Buy 8 Jul 2020
Value £15,444.00 | Price 3.51 | Shares 4,400
Buy 12 May 2020
Value €15,139.30 | Price 4.33 | Shares 3,500
Buy 26 Oct 2018
Value £16,580.00 | Price 0.83 | Shares 20,000
Buy 17 Sep 2018
Value £4,414.00 | Price 1.00 | Shares 4,414
Buy 21 Jun 2018
Value £8,520.00 | Price 0.71 | Shares 12,000
Buy 21 Jun 2018
Value £17,040.00 | Price 0.71 | Shares 24,000
Buy 21 Jun 2018
Value £8,520.00 | Price 0.71 | Shares 12,000
Buy 21 Jun 2018
Value £17,670.00 | Price 0.57 | Shares 31,000
Buy 21 Jun 2018
Value £8,400.00 | Price 0.56 | Shares 15,000
Through Matti Karvonen, a closely affiliated person
Buy 21 Jun 2018
Value £1,125.00 | Price 0.75 | Shares 1,500
Buy 21 Jun 2018
Value £3,484.00 | Price 0.67 | Shares 5,200
Buy 21 Jun 2018
Value £4,424.00 | Price 0.56 | Shares 7,900
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-31 2026-03-01 B Purchase
Tuomo Pätsi

Non-Executive Chairman

Director
59,740
13.79
€1,156,483 		59,740 13.79 €1,156,483
2026-03-25 2026-03-01 B Purchase
Sirpa Jalkanen

PCA
87,167
265.53
€1,791,182 		87,167 265.53 €1,791,182
2024-04-04 2024-04-03 B Purchase
Tuomo Pätsi

Director

Executive Director
12,958
258.14
€3,795,489 		12,958 258.14 €3,795,489
2024-04-04 2024-04-03 B Purchase
Sirpa Jalkanen

Director

Executive Director
79,999
1.50
€119,998 		79,999 1.50 €119,998
2024-04-04 2024-04-03 B Purchase
2.2
Markku Jalkanen

Director

Executive Director
79,999
1.50
€119,998 		79,999 1.50 €119,998
2023-10-27 2023-10-12 S Sale
John Poulos

Non-executive Director

Executive Director
5,000
3.83
€19,130 		5,000 3.83 €19,130
2023-10-27 2023-10-03 S Sale
John Poulos

Non-executive Director

Executive Director
5,000
3.72
€18,604 		5,000 3.72 €18,604
2022-04-08 2022-04-05 B Purchase
2.2
Markku Jalkanen

Chief Executive Officer

Officer
25,000
2.82
€70,532 		25,000 2.82 €70,532
2020-07-08 2020-07-08 B Purchase
2.4
Toni HÄonninen

Chief Financial Officer

Officer
4,400
3.51
£15,444 		4,400 3.51 £15,444
2020-05-12 2020-05-12 B Purchase
2.4
Toni HÄonninen

Chief Financial Officer

Officer
3,500
4.33
€15,139 		3,500 4.33 €15,139
2018-11-06 2018-10-26 B Purchase
1.1
Matti Karvonen

VP Drug Development, Chief Medical Officer

Officer
20,000
0.83
£16,580 		20,000 0.83 £16,580
2018-09-18 2018-09-17 B Purchase
1.4
Minja Pfeiffer

Chief Medical Officer

Officer
4,414
1.00
£4,414 		4,414 1.00 £4,414
2018-06-21 2018-06-21 B Purchase
3.2
Juho Jalkanen

Chief Development Officer

Officer
12,000
0.71
£8,520 		12,000 0.71 £8,520
2018-06-21 2018-06-21 B Purchase Mehto Saima Kuolinpesä

Chief Development Officer

Officer
24,000
0.71
£17,040 		24,000 0.71 £17,040
2018-06-21 2018-06-21 B Purchase
2.2
Markku Jalkanen

Chief Development Officer

Officer
12,000
0.71
£8,520 		12,000 0.71 £8,520
2018-06-21 2018-06-21 B Purchase
1.4
Minja Pfeiffer

Chief Development Officer

Officer
31,000
0.57
£17,670 		31,000 0.57 £17,670
2018-06-21 2018-06-21 B Purchase
1.1
Matti Karvonen

Chief Executive Officer

Through Matti Karvonen, a closely affiliated person Officer
15,000
0.56
£8,400 		15,000 0.56 £8,400
2018-06-21 2018-06-21 B Purchase
3.1
Pessi Honkasalo

Medical Director

Executive Director
1,500
0.75
£1,125 		1,500 0.75 £1,125
2018-06-21 2018-06-21 B Purchase
3.3
Yrjö Wichmann

Corporate Legal Counsel
5,200
0.67
£3,484 		5,200 0.67 £3,484
2018-06-21 2018-06-21 B Purchase Susanna Hedenström

Chief Financial Officer

Officer
7,900
0.56
£4,424 		7,900 0.56 £4,424
Explore more

More insider trading research around Faron Pharmaceuticals Oy

More insider trades in Finland
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in Europe